IRVINE, Calif., April 19 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation , a leading developer of surgical products and accessories used in angina-relieving procedures, today announced its participation in the 2007 Cardiothoracic Technology Symposium being held April 20th through April 22nd 2007 at the University of Cincinnati Center for Surgical Innovation.
Participants in the 3 day course include 60 cardiothoracic surgery fellows and residents. This is the second annual symposium, which is coordinated by the Thoracic Surgeons Residents Association. Cardiogenesis is participating in the course, including the hands-on wet lab. Gary S. Allen, MD of Orlando, Florida will be presenting on transmyocardial revascularization (TMR) and directing a wet lab utilizing the Cardiogenesis minimally invasive PEARL delivery systems, which is currently being evaluated clinically under an Investigational Device Exemption.
Richard P. Lanigan, President stated, "We are excited to participate in this training forum for cardiothoracic residents as they are preparing for their transition into clinical practice. We are fortunate to have Dr. Allen, the principal investigator for our Thoracoscopic PEARL 8.0 clinical study, available to direct the hands-on wet lab with our advanced minimally invasive systems. These residents are well versed on port access technique and will be trained with our leading technology for the delivery of TMR upon completion of the course."
In conjunction with the Symposium, Cardiogenesis is launching LearnTMR.com, a new educational website for surgeons and healthcare professionals, to coincide with the Cardiothoracic Technology Symposium. LearnTMR.com provides essential information regarding TMR in a thorough manner, including testing for essential content.
"The combination of the online training for the residents in attendance with the hands on wet lab utilizing our advanced technology will result in the certification of the participants on the Cardiogenesis TMR platform upon completion of the symposium. The new web based training modules will provide improved consistency and efficiency of all of our training programs going forward, as well as allow us to make more effective use of the on-site physician training time," Lanigan explained.
The Cardiothoracic Technology Symposium is one component of the Company's 2007 TMR physician training plan. Regional and national training programs will be provided for training of attending cardiothoracic surgeons at current Cardiogenesis TMR centers and for new centers established throughout the year.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The Company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the Company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.
For more information on the Company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.
With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR or PMC procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; restrictions contained in our convertible debt obligations requiring the issuance of shares rather than repayment in cash; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Cardiogenesis CorporationCONTACT: William R. Abbott, Senior Vice President and Chief FinancialOfficer of Cardiogenesis Corporation, +1-949-420-1800
